ࡱ >
\ p None B a = c @ = Z ?N*8 X" 1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial1 Arial General `
Table 1 jP 4
SLE RA Controls No. of subjects (F:M ratio) 115 (105:10) 157 (127:30) 31 (26:5) Disease duration (months) 1 0 9 . 3 6 3 . 8 ( 1 3 3 6 ) 9 6 . 6 8 5 . 4 ( 2 4 1 7 ) _ Number of arthritic joints 6 . 7 5 . 6 ( 0 2 6 ) # Patients having proteinuria 19 Patients having arthritis 6 155 Patients having skin rash 3 _ Patients having vasculitis 1 C3c (mg/dl) 8 7 . 1 2 5 . 9 ( 1 8 . 6 1 8 8 . 0 )
C4 (mg/dl) 1 7 . 7 1 2 . 3 ( 1 . 5 0 1 2 2 . 0 ) Anti-dsDNA (mg/dl) 1 7 1 . 3 1 2 8 . 9 ( 3 5 . 3 5 4 6 . 9 ) Rheumatoid factor (IU/ml) 1 3 7 . 8 2 4 6 . 2 ( 1 . 2 1 2 0 0 . 0 ) ESR (mm/hr) 2 4 . 6 2 0 . 9 ( 2 . 0 1 0 1 . 0 )
CRP (mg/L) 9 . 3 1 7 . 2 ( 0 . 2 1 3 3 . 2 ) SLEDAI 3 . 4 2 . 6 ( 0 1 2 . 0 ) DAS28 4 . 3 1 . 3 ( 1 . 9 7 . 3 ) Prednisolone and equivalent* (mg/day) 1 1 . 7 8 . 4 ( 2 . 5 5 0 . 0 ) : 7 6 . 5 % 6 . 0 3 . 1 ( 2 . 5 1 5 ) : 3 4 % One DMARD* 24.4% 19.7% Two or more DMARDs* 73.0% 72.0% Biologicals* - 24.8%
d MbP?_ % * + &P &F